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ABSTRACT
Objective Endoscopic surveillance for Barrett’s
oesophagus (BO) is limited by sampling error and the
subjectivity of diagnosing dysplasia. We aimed to
compare a biomarker panel on minimal biopsies directed
by autoﬂuorescence imaging (AFI) with the standard
surveillance protocol to derive an objective tool for
dysplasia assessment.
Design We performed a cross-sectional prospective
study in three tertiary referral centres. Patients with BO
underwent high-resolution endoscopy followed by AFI-
targeted biopsies. 157 patients completed the biopsy
protocol. Aneuploidy/tetraploidy; 9p and 17p loss of
heterozygosity; RUNX3, HPP1 and p16 methylation;
p53 and cyclin A immunohistochemistry were assessed.
Bootstrap resampling was used to select the best
diagnostic biomarker panel for high-grade dysplasia
(HGD) and early cancer (EC). This panel was validated in
an independent cohort of 46 patients.
Results Aneuploidy, p53 immunohistochemistry and
cyclin A had the strongest association with dysplasia in
the per-biopsy analysis and, as a panel, had an area
under the receiver operating characteristic curve of 0.97
(95% CI 0.95 to 0.99) for diagnosing HGD/EC. The
diagnostic accuracy for HGD/EC of the three-biomarker
panel from AFI+ areas was superior to AFI− areas
(p<0.001). Compared with the standard protocol, this
panel had equal sensitivity for HGD/EC, with a 4.5-fold
reduction in the number of biopsies. In an independent
cohort of patients, the panel had a sensitivity and
speciﬁcity for HGD/EC of 100% and 85%, respectively.
Conclusions A three-biomarker panel on a small
number of AFI-targeted biopsies provides an accurate
and objective diagnosis of dysplasia in BO. The clinical
implications have to be studied further.
INTRODUCTION
Barrett’s oesophagus (BO) is the only recognised
precursor to oesophageal adenocarcinoma (OAC)1
whose incidence has dramatically increased over
the last 40 years in the Western world.2–4 Despite
the contradictory evidence on the beneﬁt of endo-
scopic monitoring for BO,5 6 all specialist societies
recommend surveillance with a protocol entailing
four-quadrant random biopsies every 2 cm (Seattle
protocol).7 8 However, this protocol is time
consuming and invasive with subsequent poor
adherence by endoscopists.9 10 In addition, dyspla-
sia and early cancer (EC) can be inconspicuous,
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Signiﬁcance of this study
What is already known on this subject?
▸ Endoscopic surveillance for Barrett’s
oesophagus with random 4-quadrant biopsies
has limitations including sampling error and
subjectivity of dysplasia diagnosis.
▸ Endoscopic red-ﬂag techniques, such as
autoﬂuorescence imaging (AFI), can improve
diagnostic yield, but cannot not replace random
biopsies.
▸ Some molecular biomarkers correlate with the
dysplasia status of patients with Barrett’s
oesophagus.
What are the new ﬁndings?
▸ We have validated 8/9 molecular biomarkers in
an independent laboratory for the ﬁrst time. Of
these a small 3-biomaker panel including p53
immunohistochemistry, cyclin A and aneuploidy
had the best correlation with prevalent
dysplasia.
▸ AFI positivity correlated with molecular
biomarker status even in the absence of
dysplasia.
▸ To determine the overall patient dysplasia
status the 3-biomaker panel applied to AFI-
targeted biopsies had equivalent sensitivity for
high grade dysplasia and early cancer
compared to the current clinical Seattle
protocol, with a 4.5 fold reduction in the
number of biopsies required.
How might it impact on clinical practice in
the foreseeable future?
▸ The combination of molecular biomarkers and
AFI may a useful tool for surveying patients
with long segment of Barrett’s oesophagus as
it reduces the number of biopsies needed
without loss of diagnostic accuracy.
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leading to sampling error.11 Hence, clinical justiﬁcation and
cost-effectiveness of endoscopic surveillance has been ques-
tioned, especially following recent evidence that the cancer risk
in BO is lower than previously thought.12 13
Autoﬂuorescence imaging (AFI) can improve recognition of
inconspicuous dysplasia.14–16 Two previous cross-over studies
have shown that, although AFI improves detection of dysplasia,
it has a high false-positive rate (>60%) and its accuracy was not
sufﬁcient to replace the Seattle protocol.14 15
An important limitation of endoscopic surveillance is the sig-
niﬁcant interobserver variability in the histopathological diagno-
sis of dysplasia.17 18 This could be improved by molecular
biomarkers that could provide more objective scores and cut-off
values. Some of these, such as overexpression of p53 and cyclin
A, methylation of speciﬁc genes, loss of heterozygosity (LOH) at
the 17p and 9p loci and DNA ploidy abnormalities, associate
with dysplasia.19–24 However, with the exception of p53 expres-
sion, these biomarkers have only been tested by single groups in
single, retrospective cohorts of patients and this has hampered
their translation into clinical practice. In addition, there is a lack
of prospective studies testing multiple biomarkers in the same
prospective cohort to identify the smallest, clinically applicable
panel with the highest diagnostic accuracy. In this study, we used
AFI to enrich our biopsy samples prior to biomarker analysis
since we hypothesised that these areas may correlate with a ﬁeld
of molecular abnormalities indicative of the overall dysplasia
status of the patient and hence reduce sampling bias.
Therefore, the primary aim of this prospective study was to
compare the accuracy of a panel of molecular biomarkers on
AFI-directed biopsies with the conventional quadrantic biopsies
every 2 cm for the diagnosis of high-grade dysplasia (HGD) and
EC. The secondary aims were (i) assessment of diagnostic accur-
acy for the biomarkers for any grade of dysplasia and (ii) valid-
ation of a large panel of biomarkers in an independent
prospective study by an independent laboratory.
METHODS
Patients and setting
The study was approved by the Cambridgeshire 2 Research
Ethics Committee (09/H0308/118). For the generation of the
biomarker panel, a training cohort of 175 patients was recruited
prospectively between April 2009 and October 2011 from three
centres. For the validation of the panel, an independent cohort
of 46 patients was prospectively recruited between March 2012
and April 2013 at a single institution (Cambridge). Inclusion
criteria were age >18 years, known BO with minimum length
of C≥2 or C<2M≥4 according to the Prague classiﬁcation,25
referral for evaluation of dysplastic BO or follow-up postendo-
scopic resection for HGD/EC. Short segments of <2 cm were
excluded due to the excess of AFI-false positivity at the gastro-
oesophageal junction and since sampling error is not such an
issue for these cases.26 Exclusion criteria were oesophagitis (Los
Angeles grade ≥B); previous upper gastrointestinal (GI) surgery
(with the exception of Nissen fundoplication) or known
upper-GI tract abnormality (eg, pharyngeal pouch); coagulopa-
thy or anticoagulant/antiplatelet therapy for high-risk condi-
tions; active or severe cardiopulmonary disease or liver disease;
dysphagia; and special communication needs.
Endoscopic procedure
Patients were endoscoped with FQ260Z endoscopes (Olympus
Inc, Tokyo, Japan) as previously described.14 Five endoscopists
performed the procedures, but in order to uniform the inter-
pretation of the AFI signal, the three endoscopists with less
experience in AFI performed at least 30 procedures prior to the
study under supervision of more experienced endoscopists
( JJGHMB and KR). The oesophagus was inspected ﬁrst by
white light high-resolution endoscopy (HRE) to detect visible
lesions (see online supplementary ﬁgure S1A). Then, in AFI
mode, AFI-positive (AFI+) areas (violet-purple in colour) were
carefully mapped. A representative AFI-negative (AFI–) area
(green colour) was then selected as a negative control (see
online supplementary ﬁgure S1B). In patients who had diffuse
patchy AFI positivity throughout the BO (n=8), an AFI– area
was not selected, but they were included in the per-biopsy
(ﬁgure 2) and ﬁnal per-patient analysis (ﬁgure 4).
Biopsy and histology
Each AFI+ area and one AFI− area were biopsied for biomarker
analysis and histopathology (see online supplementary ﬁgure
S1A). Up to a maximum of four AFI+ areas were included in
the research protocol; however, small AFI+ areas (<1 cm)
within 1 cm from the gastro-oesophageal junction were
excluded due to the well-known false positivity in close proxim-
ity to the gastric folds.27 Where possible (depending on the size
of the AFI+ area), a maximum of three biopsies were taken in
the following order of priority: one biopsy in formalin, one
snap frozen biopsy in 10% dimethysulfoxide (DMSO) and one
biopsy snap frozen dry. For AFI+ areas larger than 1 cm, two or
more biopsies were taken for histology to minimise sampling
error, whereas AFI+ areas with a complex shape were consid-
ered as multiple AFI+ areas (see online supplementary ﬁgure
S1B). Histopathological assessment of each AFI-targeted area
relied on biopsies stored in formalin. Random biopsies were
then taken according to the Seattle protocol. The histology was
assessed by an expert GI pathologist at the respective participat-
ing centre according to the Vienna classiﬁcation.28 All dysplastic
cases, including indeﬁnite for dysplasia (ID), were then reviewed
by a second pathologist, with random pairing of the initial path-
ologist with one of the pathologists from the other centres. Four
pathologists took part in initial assessment, but only three parti-
cipated in the reviewing process. In case of disagreement, con-
sensus was reached through a review process, and this diagnosis
was considered as the ﬁnal histological outcome. Cases with ID
without deﬁnite dysplasia after consensus review were regarded
as non-dysplastic (NDBO). In accordance with the Vienna classi-
ﬁcation cases of HGD, carcinoma in situ and intramucosal
adenocarcinoma were grouped together (HGD/EC) as they rep-
resent a common endpoint for endoscopic therapeutic interven-
tion.7 29 For the purpose of the biomarker analysis, all biopsies
taken using the AFI mode were regarded as AFI-targeted (AFI+
and AFI−). With regards to the overall per-patient histopatho-
logical diagnosis, we considered diagnoses made using (a) the
current clinical standard (Seattle protocol, ie, biopsies on areas
visible on HRE+ quadrantic random biopsies) and (b) the
overall histology (a+ histology on AFI-targeted biopsies).
Biomarker analyses
All molecular analyses were done at the Medical Research
Council, Cancer Unit (Cambridge, UK). The panel of molecular
biomarkers analysed in the training cohort (nine-biomarker
panel) comprised aneuploidy, G2/tetraploidy, LOH at 9p and
17p loci, hypermethylation of p16, RUNX3, HPP1 and immu-
nohistochemistry (IHC) for p53 and cyclin A. Details of the
molecular analyses are provided in the online supplementary
material.
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Sample size and power
Previous data suggest that single biomarkers have a sensitivity
for HGD/EC varying between 60 and 87%; however, we
assumed that, when combined into a panel, biomarkers could
have 90–95% sensitivity and 85–95% speciﬁcity. For a sensitiv-
ity of 90%, we calculated that to have an accuracy of 10% (95%
CI ±10%) we needed to recruit at least 35 patients with HGD/
EC.
Statistics
For the purpose of the per-biopsy analysis, each AFI-targeted
area was classiﬁed with (1) AFI status (AFI+ or AFI−), (2)
binary outcome of the nine biomarkers and (3) histological diag-
nosis. c2 tests were used to compare differences between groups.
A p value <0.05 was considered statistically signiﬁcant.
Interobserver agreement was assessed by κ statistics. For the
pathological diagnosis, agreement among three expert patholo-
gists for a diagnosis of any grade of dysplasia was expressed as
weighted κ value. For the endoscopic location of AFI-targeted
areas, the agreement was expressed as κ value; agreement
among endoscopists was deﬁned as their speciﬁcation of the epi-
centre of the AFI+ area within 30° of the endoscopic view. For
this analysis, 20 random AFI pictures were selected by two
authors (DFB and MKS) and assessed by three authors (MDP,
KR and JJGHMB).
The statistical analysis consisted of three stages: (1) per-biopsy
analysis (correlation between biomarkers and histological
outcome in individual targeted areas); (2) per-patient analysis
(correlation between overall biomarker result and overall histo-
logical outcome in individual patients); and (3) comparison
between AFI+ versus AFI− areas (comparative analysis of bio-
marker diagnostic accuracy for dysplasia in biopsies from AFI+
vs AFI− areas).
To obtain means, medians and SDs for various statistics, we
relied on two types of simulations, multiple imputation (MI)
and bootstrap resampling. Missing values were imputed by MI
as it is generally preferred to impute values than to drop
samples with missing values.30 31 The only assumption for the
MI procedure is that the missingness pattern does not depend
on missing values, but it may depend on observed values.32
Since missing values are mostly related to the size of AFI+
areas, we assumed that this correlation could be captured in the
observed biomarker values and missing values imputed. The
imputation model included the nine biomarkers and the histo-
logical diagnosis as variables. Five independent data sets were
imputed, and they were included in the analysis together with
the original database, where missing values were removed. The
variation in the imputed values between the MI data sets reﬂects
uncertainty about the missing values.
Bootstrap resampling was used to obtain estimates of para-
meters and their SEs from ﬁnite sample sets to allow conclu-
sions to be drawn about the population in general.33 B-artiﬁcial
sample data sets were obtained from the original set of samples,
where B is a suitably large number (in the hundreds or thou-
sands). Each artiﬁcial data set was drawn randomly with equal
size to the original data set. After selection into the bootstrap
set, samples were put back into the original pool and could be
selected again. Multiple rounds of a random selection of sub-
samples were performed and the calculated accuracy of the par-
ameter of interest was validated in the remaining subsample.
This prevented inﬂating the diagnostic performance of biomar-
kers by applying the model to the same data set from which it
was developed (overﬁtting). Further details of these analyses are
provided in the online supplementary material.
Details of the statistical methodology used for the generation
and the validation of the biomarker panel are described in the
online supplementary material.
Table 1 Demographics, histological stage and endoscopic
characteristics of AFI+ areas for patients included in training and
validation cohorts
Training cohort Validation cohort p Value
Variables
Number of patients 157 46 N/A
Male: female (%) 79:21 93:7 0.06
Mean age (range) 66.4 (35–87) 68.7 (35–84) 0.23
Mean length of BO
in cm (range)
7.3 (2–17) 7.6 (3–18) 0.85
Histological diagnosis
NDBO 99 (63%) 22 (56.4%) 0.24
LGD 21 (13.4%) 8 (20.5%)
HGD 24 (15.3%) 3 (7.7%)
EC 13 (8.3%) 6 (15.4%)
Endoscopic features
Number of AFI+ areas 229 108 N/A
AFI+ areas visible on HRE 28.4% 21% 0.15
AFI+ areas with HGD/EC 21.1% 15.4% 0.32
AFI, autofluorescence imaging; EC, early cancer; HGD, high-grade dysplasia;
HRE, high-resolution endoscopy; LGD, low-grade dysplasia; NDBO, non-dysplastic
Barrett’s oesophagus.
Figure 1 Strategy for the generation of the biomarker panel. χ2 test
showed that from the initial panel of nine biomarkers seven
signiﬁcantly associated with a diagnosis of high-grade dysplasia/early
cancer (HGD/EC) in the corresponding biopsy (arm 1—left side). To
identify a small biomarker panel, bootstrap resampling on ﬁve imputed
and one original database was applied (arm 2—right side). Both
per-biopsy and per-patient analyses identiﬁed the same
three-biomarker panel as the best diagnostic panel for HGD/EC.
Endoscopy
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All the analyses were performed using SPSS V.19.0 (SPSS Inc,
Chicago, Illinois, USA) and R V.2.15.2.
RESULTS
Of the 175 participants recruited as part of the training cohort, 18
were excluded because of either a lack of biopsies for laboratory
tests (n=4) or breach of biopsy protocol (eg, biopsy mislabelling,
no research biopsy in AFI+ areas taken, no random biopsies
taken) (n=14). From the remaining 157 participants, we obtained
373 AFI-targeted biopsies (AFI+:AFI−=230:143), which were
processed for biomarkers and included in the per-biopsy analysis.
The validation cohort consisted of 46 patients, from which
155 AFI-targeted biopsies were taken (AFI+:AFI−=108:47).
There were no signiﬁcant differences between the two cohorts in
the demographics and histological outcomes as well as character-
istics of AFI+ areas; however, the validation cohort had a slightly
higher number of AFI+ areas per patient (table 1). The overall
interobserver agreement among three expert pathologists for a
diagnosis of any grade of dysplasia was ‘moderate’ (weighted κ
value 0.56, SE 0.055). With reference to the interpretation of the
AFI signal for targeting biopsies, the overall agreement for locating
the area of interest among observers was ‘good’ (κ value 0.68, SE
0.104) and the interobserver variability did not change signiﬁ-
cantly when the agreement between two expert endoscopists was
compared with the agreement between expert and non-expert
endoscopists.
Association of biomarkers with dysplasia (per-biopsy
analysis)
We ﬁrst sought to identify a small biomarker panel with the best
diagnostic accuracy for prevalent dysplasia. To this end, we
identiﬁed nine biomarkers that had the most robust correlation
with dysplasia in BO based on published phase III and IV clin-
ical studies.19–24 Figure 1 shows the strategy used for the
Table 2 Association of biomarkers with dysplasia in the per-biopsy analysis
Biomarker
Missing
values (%)
Biomarker
outcome
HGD/EC Any dysplasia
No Yes p Value No Yes p Value
HPP1 methylation 19.1 Negative 59 (22.9%) 3 (7.1%) 0.02 56 (24.0%) 6 (9.0%) <0.01
Positive 199 (77.1%) 39 (92.9%) 177 (76.0%) 61 (91.0%)
RUNX3 methylation 19.1 Negative 102 (39.5%) 6 (14.3%) <0.01 97 (41.6%) 11 (16.4%) <0.01
Positive 156 (60.5%) 36 (85.7%) 136 (58.4%) 56 (83.6%)
p16 methylation 19.1 Negative 143 (55.4%) 12 (28.6%) <0.01 132 (56.7%) 23 (34.3%) <0.01
Positive 115 (44.6%) 30 (71.4%) 101 (43.3%) 44 (65.7%)
p53 IHC 13.2 Negative 196 (70.5%) 3 (6.8%) <0.01 189 (76.8%) 10 (13.2%) <0.01
Positive 82 (29.5%) 41 (93.2%) 57 (23.2%) 66 (86.8%)
Cyclin A IHC 14.0 Negative 238 (85.0%) 8 (20.5%) <0.01 223 (88.8%) 23 (33.8%) <0.01
Positive 42 (15.0%) 31 (79.5%) 28 (11.2%) 45 (66.2%)
Tetraploidy 19.7 Negative 182 (69.2%) 20 (57.1%) 0.15 171 (72.2%) 31 (50.8%) <0.01
Positive 81 (30.8%) 15 (42.9%) 66 (27.8%) 30 (48.2%)
Aneuploidy 19.7 Negative 232 (88.2%) 10 (28.6%) <0.01 216 (91.1%) 26 (42.6%) <0.01
Positive 31 (11.8%) 25 (71.4%) 21 (8.9%) 35 (57.4%)
17p LOH 27.4 Negative 112 (49.3%) 7 (16.7%) <0.01 107 (51.9%) 12 (19.0%) <0.01
Positive 115 (50.7%) 35 (83.3%) 99 (48.1%) 51 (81.0%)
9p LOH 28.5 Negative 43 (19.2%) 5 (12.2%) 0.29 40 (19.5%) 8 (13.3%) 0.27
Positive 181 (80.8%) 36 (87.8%) 165 (80.5%) 52 (86.7%)
Each p value is obtained from a χ2 test on the 2×2 table to its left. Any dysplasia refers to combination of low-grade dysplasia (LGD), HGD and EC.
EC, early cancer; HGD, high-grade dysplasia; IHC, immunohistochemistry; LOH, loss of heterozygosity.
Figure 2 A three-biomarker panel including p53
immunohistochemistry (IHC), cyclin A IHC and aneuploidy has high
diagnostic accuracy for dysplasia. (A) Inclusion frequencies of the nine
biomarkers in 100 bootstrap samples for each MI database (n=5) and
the original database (n=1). A stringent cut-off of 90 for the median
over all six databases was used to select the best biomarkers. p53 IHC,
cyclin A IHC and aneuploidy had median inclusion frequency above the
threshold. (B,C) Area under the curve (AUC) for the diagnosis of any
grade of dysplasia (B) and high-grade dysplasia/early cancer (HGD/EC)
only (C) was calculated using the panel of biomarker selected in (A).
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generation of the panel. The nine biomarkers were tested in the
AFI-targeted biopsies from the training cohort to assess their
association with dysplasia on a per-biopsy basis. As shown in
table 2, all of the biomarkers associated with the presence of
conﬁrmed dysplasia, with the exception of 9p LOH (p16).
When restricting the analysis to the association between
biomarkers and HGD/EC, we found similar results, in that only
tetraploidy and 9p LOH lacked statistical signiﬁcance.
Since large numbers of biomarkers are difﬁcult to apply in
the clinical setting, we used a strict statistical methodology to
identify a small biomarker panel. The data set had 20% of
missing values as some AFI+ areas were not sufﬁciently large to
allow three biopsies as per protocol (table 2). We used bootstrap
resampling on the original database as well as on ﬁve imputed
databases to account for missing values. This statistical method-
ology has been previously developed to handle data sets with up
to 50% of missing data in clinical studies.34 We concentrated on
the highest histological outcome for this analysis (HGD/EC) as
this is what currently triggers therapeutic decisions according to
clinical guidelines. We found that two IHC markers (p53 and
cyclin A) and aneuploidy had the highest rate of inclusion in
best bootstrap models (ﬁgure 2A), and for this reason they were
selected to form a three-biomarker panel. On a per-biopsy ana-
lysis, this panel had area under the curves (AUCs) of 0.93 (95%
CI 0.89 to 0.98) and 0.97 (95% CI 0.95 to 0.99) for a diagnosis
of any grade of dysplasia and HGD/EC, respectively (ﬁgure 2B,
C). These data showed that these three biomarkers have the
strongest association with dysplasia and could be combined into
a panel to aid clinical diagnosis.
Association between molecular biomarkers and AFI status
In order to translate the diagnostic accuracy for dysplasia of the
biomarker panel from a single biopsy to a per-patient level, we
determined that the biopsies should be targeted using an
imaging tool. Hence, we then asked whether AFI positivity cor-
relates with molecular abnormalities. We ﬁrst analysed the asso-
ciation between individual biomarker outcome and AFI status of
the corresponding endoscopic area. Aneuploidy, 17p LOH, p53
IHC and cyclin A signiﬁcantly associated with AFI positivity
(p<0.05) (see online supplementary table S1). Since dysplasia
could represent a confounding factor, we looked at this associ-
ation after exclusion of dysplastic areas and found that aneu-
ploidy and p53 IHC retained a signiﬁcant association with AFI
positivity (see online supplementary table S1). To conﬁrm the
clinical utility of this association, we compared the accuracy for
an overall diagnosis of HGD/EC of the three-biomarker panel in
AFI+ areas versus AFI− areas (ﬁgure 3). Notably, average AUCs
in all six databases were signiﬁcantly higher for the three-
biomarker panel assessed on AFI+ areas compared with AFI−
areas. We therefore concluded that AFI positivity is associated
with an enrichment of biomarkers and is a suitable tool to guide
biopsies for biomarkers.
Internal validation of the three-biomarker panel
(per-patient analysis)
We sought to conﬁrm that the biomarker panel selected in the
per-biopsy analysis could correctly classify patients based on
their highest grade of histological dysplasia. From a pool of 9
biomarkers, there are 84 different combinations of 3 biomarkers
and 36 combinations of 2 biomarkers. We calculated the diag-
nostic accuracy of these 120 biomarker panels in the 2000 boot-
strap samples generated from the original database. Strikingly,
the best diagnostic accuracy was achieved by the same panel
Figure 3 Diagnostic accuracy for high-grade dysplasia/early cancer
(HGD/EC) of the three-biomarker panel assessed on autoﬂuorescence
imaging-positive (AFI+) areas and AFI− areas. This analysis was
performed on the 114 patients with biopsies available on both
AFI+ and AFI− areas, after exclusion of patients without AFI positivity
(n=35) and those with diffuse AFI positivity (n=8). The area under the
curve (AUC) for a diagnosis of overall HGD/EC was calculated using the
three-biomarker panel from AFI+ areas and AFI− areas in 2000
bootstrap samples from ﬁve imputed databases (MI) and the original
database (OD). In this plot, each box represents the median AUC with
ﬁrst and third quartiles for the bootstrap samples of each group and
the whiskers include data within 1.5 IQR of the upper and lower
quartile. Outliers are depicted separately. *** indicates p value <0.001.
Figure 4 Flow chart of biomarker outcome in patient from the
training cohort with full three-biomarker data set. Using a cut-off of
two abnormal biomarkers to diagnose patients with prevalent
high-grade dysplasia/early cancer (HGD/EC), the three-biomarker panel
only missed one patient with HGD/EC. Ten patients with non-dysplastic
Barrett’s oesophagus (NDBO) or LGD were classiﬁed as high risk for
HGD/EC. The sensitivity and speciﬁcity of three-biomarker panel for a
diagnosis of HGD/EC were 95.8% (95% CI 76.9% to 99.8%) and
88.6% (95% CI 79.7% to 94.1%), respectively. LCD, low-grade
dysplasia.
Endoscopy
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identiﬁed in the per-biopsy analysis (p53 IHC, cyclin A IHC
and aneuploidy), with a cut-off of two positive biomarkers (see
online supplementary table S2). We therefore took this panel
forward to determine histological outcome in the patients from
the training cohort that had the three-biomarker full data set
(n=112). In keeping with the results from bootstrap resampling,
a cut-off of two biomarkers positive had the best accuracy (see
online supplementary table S3). Using this cut-off, only one
patient with HGD was misclassiﬁed with a low-risk biomarker
signature (ﬁgure 4 and table 3). The biomarker panel had a sen-
sitivity and a speciﬁcity of 95.8% (95% CI 76.9% to 99.8%)
and 88.6% (95% CI 79.7% to 94.1%), respectively, for a diag-
nosis of HGD/EC, and 74.4% (95% CI 57.6% to 86.4%) and
94.5% (95% CI 85.8% to 98.2%), respectively, for a diagnosis
of any grade of dysplasia. By comparison, the Seattle protocol
had similar sensitivities, namely, 95.8% (95% CI 76.9% to
99.8%) for a diagnosis of HGD/EC (p=1.0 when compared
with three-biomarker panel) and 84.6% (95% CI 68.8% to
93.6%) for a diagnosis of any grade of dysplasia (p=0.26)
(table 3). Relying on the histology of AFI+ areas, the sensitivity
for HGD/EC was lower at 91.7%, although this difference was
not statistically signiﬁcant. Importantly, using this novel
approach 2.8 biopsies per patient were taken on average com-
pared with 12.8 for the standard biopsy protocol (p<0.001)
(table 3).
External validation of the three-biomarker panel
We then tested the biomarker panel in an independent group of
46 patients. The panel had a sensitivity and a speciﬁcity of
100% and 85% (95% CI 98.9% to 95.0%), respectively, for a
diagnosis of HGD/EC, and 73.9% (95% CI 51.6% to 89.7%)
and 100%, respectively, for a diagnosis of any grade of dysplasia
(see online supplementary table S4). The Seattle protocol
missed two cases of HGD/EC, which translated into a sensitivity
of 83.3% for a diagnosis of HGD/EC (p=0.14 when compared
with three-biomarker panel) and 91.3% for a diagnosis of any
grade of dysplasia (p=0.12), but relied on a signiﬁcantly higher
number of biopsies (p<0.001).
DISCUSSION
In the present study, we devised a novel strategy in which
advanced endoscopic imaging can be used in BO to direct
biopsy sampling for biomarkers. Single biomarkers or panels of
biomarkers have been shown to correlate with dysplasia20 22 23 35
and in some cases to estimate the individual risk of progres-
sion.22 23 35–37 This prospective multicentre phase IV study
evaluated nine biomarkers with the most robust published data,
and, to our knowledge, is the ﬁrst study that has validated such
a large panel in a single patient cohort and in an independent
laboratory. The rationale for using a biomarker panel stems
from evidence that a combination of biomarkers performs
better than single biomarkers on their own.35 Clinical applic-
ability of biomarkers relies on the feasibility of the speciﬁc
laboratory assays, low enough costs and a manageable number
of assays if combined into a panel. The panel identiﬁed in this
study satisﬁes these criteria. p53 and cyclin A rely on IHC,
which is a routine technique in pathology laboratories. Of these,
p53 is currently already employed by some pathologists to
aid in the diagnosis of dysplasia19 20 and has been recom-
mended in the revised British guidelines.38 For the evaluation
of aneuploidy, we used ﬂow cytometry on frozen samples, as
previously published.35 For future clinical applications, image
cytometry (IC) is an alternative technique applicable to parafﬁn
sections and has been recently shown to be comparable to ﬂow
cytometry in BO.39 Hence, in the future, having reﬁned the
number of biomarkers from 9 to 3, the panel can be applied
from a single diagnostic biopsy stored in formalin.
In this study, we hypothesised that AFI positivity might cor-
relate with a ﬁeld of molecular abnormality related to dysplasia
in BO. Indeed, we found that aneuploidy and p53 abnormalities
signiﬁcantly correlated with AFI positivity independently of dys-
plasia within that AFI+ area. DNA is known to be a weak ﬂuor-
ophore; therefore, the loss of autoﬂuorescence may be
explained by the increased DNA content observed in aneu-
ploidy. Similarly, p53 is a key gene in the control of DNA ampli-
ﬁcation and proliferation of aneuploid cells,40 whereas cyclin A
can be overexpressed as result of cell cycle deregulation leading
to aneuploidy.41 Inﬂammation has previously been shown to
associate with AFI false positivity.14 Since inﬂammatory path-
ways can drive genetic and epigenetic changes during carcino-
genesis in BO,42 it is possible that the AFI signal, inﬂammation
and biomarkers are all closely related.
Assessment of dysplasia in the AFI-targeted areas relied only on
diagnostic biopsies stored in formalin; therefore, there is a possibil-
ity of sampling error for focal dysplasia. To reduce this possibility,
large AFI+ areas had two or more diagnostic biopsies taken. Since
the molecular changes precede development of dysplasia and
expand over large areas of mucosa,24 we believe that the ﬁeld of
molecular abnormality is less affected by sampling error.
Notably, the new diagnostic tool had the same sensitivity for
dysplasia as the Seattle protocol with signiﬁcantly fewer biop-
sies. Therefore, this novel risk stratiﬁcation approach, which is
based on more objectively measurable outcomes, has the poten-
tial to overcome several of the major limitations of BO surveil-
lance endoscopy, including sampling error and the subjectivity
of a dysplasia diagnosis. Four pathologists with a special interest
in BO took part in this study, and still the agreement for a diag-
nosis of any grade of dysplasia was ‘moderate’. Hence, a binary
outcome of a molecular test with a predetermined cut-off value
can prove advantageous in this regard. In addition, the small
number of biopsies may lead to shorter endoscopic procedures
and a lower risk of complications. From an economic perspec-
tive, we estimated that the costs required to assess the three-
Table 3 Comparison among Seattle protocol, AFI-targeted
histology and three-biomarker panel on AFI+ areas
Seattle
protocol
+histology
AFI
+histology
AFI
+biomarkers p Value
No. of HGD/EC
missed
1 2 1 N/A
Sensitivity for
HGD/EC
95.8% 91.7% 95.8% ns
Total no. of biopsies 1385 169 310 N/A
No of biopsies per
patient
12.4 1.5 2.8 <0.001
No of biopsies for
every HGD/EC case
diagnosed
60.2 7.7 13.5 N/A
Seattle protocol includes all biopsies taken on HRE white light endoscopy (random +
targeted on macroscopically visible abnormal areas). AFI+ histology includes biopsies
taken on AFI+ areas, regardless of their appearance on HRE. AFI + biomarkers
column includes only the biopsies from AFI+ areas processed for the three-biomarker
panel.
AFI, autofluorescence imaging; EC, early cancer; HGD, high-grade dysplasia;
HRE, high-resolution endoscopy.
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biomarker panel (aneuploidy by IC + IHC for p53 and cyclin
A) on biopsies targeted by AFI were similar to the costs of the
Seattle protocol, and these costs would come down with high-
throughput assay techniques (data not shown).
This is a cross-sectional study to diagnose prevalent dysplasia,
and therefore we did not set out to analyse follow-up data.
However, it is notable that among the 10 patients in the training
cohort with a high-risk biomarker proﬁle (≥2 abnormal biomar-
kers) and no evidence of HGD/EC at the time of the endoscopy
(ﬁgure 4), 6 of them (60%) had pathological progression within
6 months (4 from low-grade dysplasia (LGD) to HGD/EC,
1 from ID to EC and 1 from ID to LGD). Assuming this could
have been prevalent disease missed by sampling error, this con-
ﬁrms that biomarkers overcome this limitation of the Seattle
protocol. However, the lack of follow-up data did not allow us
to draw conclusions concerning the clinical implications of the
novel method, especially in relation to the role of this approach
for predicting future cancer progression as compared with the
current standard of practice.
This study has several strengths. It is the ﬁrst study designed
prospectively to assess a predeﬁned group of multiple biomar-
kers in a large cohort of patients with BO and by a single
laboratory. To our knowledge, this is the largest imaging study
in BO and it has a sample size comparable to other biomarker
studies.23 35 Finally, the endoscopic protocol was carefully mon-
itored to guarantee proper training and strict adherence.
This study has some limitations. Only approximately 70% of
patients could enter the per-patient analysis in the original data-
base (112 out of 157). This is due to the fact that at the start of
the study we lacked information about which of the nine bio-
markers would outperform the others. Therefore, since not all
the AFI+ areas were large enough to allow for three research
biopsies, we evenly distributed different biomarker analyses
among the available biopsies and then used a combination of
MI and bootstrap resampling to deal with missing data.34 By
contrast, all patients included in the validation cohort could be
fully assessed with the three biomarkers, suggesting that a
smaller panel is clinically feasible. Furthermore, the patient
cohorts do not reﬂect the general BO population as enrichment
for high-risk patients was necessary to guarantee an adequate
number of pathological outcomes to correlate with biomarker
positivity. Moreover, we cannot exclude that the improved diag-
nostic accuracy of biomarkers on AFI+ areas (ﬁgure 3) is inﬂu-
enced by the higher number of AFI+ areas sampled compared
with AFI− regions. In order to maximise the molecular informa-
tion related to AFI positivity, we aimed to sample at most four
AFI+ and one AFI− area per patient. However, the ratio
between AFI+ and AFI− areas was 1.6:1 in the training cohort
and 2.3:1 in the validation cohort, suggesting that this only had
a small impact on the ﬁnal results. In addition, although AFI is
not compatible with all the endoscopic technologies available
across the world, we believe that this study has paved the way
for a new diagnostic approach based on the integration of endo-
scopic and molecular data, and in the future other advanced
imaging modalities could be used to target biopsies for bio-
marker assessment. The advantage of AFI is that, like chro-
moendoscopy, the assessment of a colour-coded image is
relatively easy and our data on the reliability of AFI signal
interpretation conﬁrmed a good level of agreement among
endoscopists. Finally, although the exclusion of patients with
short segments makes this study mostly relevant to patients
with long segment of BO, we believe that the latter group of
patients is the one that particularly beneﬁts from red-ﬂag
endoscopic techniques and biomarkers due to the higher rate
of sampling error and number of biopsies compared with
short segments of BO.
In conclusion, this study provides evidence that a three-
biomarker panel on AFI-targeted biopsies has equivalent diag-
nostic accuracy for dysplasia compared with the current gold
standard with a signiﬁcant reduction in the number of biopsies
required.
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